Today, the SVP, R&D of Codexis (NASDAQ: CDXS), James Lalonde, sold shares of CDXS for $522.1K.
Following James Lalonde’s last CDXS Sell transaction on January 09, 2017, the stock climbed by 12.7%. This is Lalonde’s first Sell trade following 3 Buy transactions.
See today’s analyst top recommended stocks >>
Based on Codexis’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $13.54 million and GAAP net loss of $3.74 million. In comparison, last year the company earned revenue of $10.35 million and had a GAAP net loss of $6.28 million. Currently, Codexis has an average volume of 311K. The Company has a Price to Book ratio of 17.9786.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $18.00, reflecting a 0.8% upside.
The insider sentiment on Codexis has been negative according to 37 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Codexis, Inc. engages in the discovery, development, and sale of proteins. It offers enzyme optimization services and developing biocatalyst products. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels.
